Development of an Adjuvant with Vaccines for Anthrax, and West Nile Virus (WNV)

炭疽和西尼罗河病毒 (WNV) 疫苗佐剂的开发

• 批准号: 9125697
• 负责人: CASEY KOONTZ
• 金额: $ 282.32万
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-30 至 2016-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9125697
• 关键词: Adjuvant; Agonist; Anthrax Vaccines; Anthrax disease; Antigens; Cell Line; Clinical; Communicable Diseases; Contracts; Development; Drug Formulations; Emerging Communicable Diseases; HIV; Hawaii; Human; Infection; Insecta; Lead; Licensing; Licensure; Lipid A; Liposomes; Modeling; Names; National Institute of Allergy and Infectious Disease; National Security; Program Development; Pseudomonas fluorescens; Public Health; QS21; Recombinant Vaccines; Recombinants; Saponin; Saponins; TLR4 gene; Technology; Testing; Vaccine Adjuvant; Vaccines; West Nile virus; base; immunogenicity; improved; pathogen; vaccine candidate

The NIAID/DAIT Adjuvant Development Program supports the development of new candidate vaccine adjuvants through immunological characterization studies and lead compound optimization, up to and including IND-enabling studies, all towards licensure for human use. Adjuvants will be studied with currently licensed or new investigational vaccines to protect against infection by NIAID emerging and re-emerging infectious disease pathogens.

NIAID/DAIT辅助开发计划通过免疫特征研究和铅复合优化（直至辅助研究）来支持新的候选疫苗佐剂的开发，所有这些佐剂都旨在获得人使用的许可。将对目前有执照或新的研究疫苗进行研究，以防止NIAID新兴和重新出现感染性疾病病原体感染。